F ortified with coffee after a night on the sleeper, I was prepared for the Intensive Care Society 'State of the Art' Meeting 2007.
The first session was 'Recent advances in the management of major trauma.' Dr Karim Brohi started with an interesting update on hypotensive resuscitation. He stated that 'goaldirected' therapy is deleterious in trauma patients with major active haemorrhage. Animal studies show that low volume resuscitation leads to improved cerebral oxygen delivery and improved outcome. He highlighted the importance of haemorrhage control and the use of titrated fluid boluses in patients with active haemorrhage.
Dr Fotheringham stepped in at very late notice to talk about non-surgical control of bleeding. His passion for the subject was obvious from the start. He gave a potted history of the topic, then showed the role of interventional radiology in blunt and penetrating trauma. The discrete nature of injury associated with penetrating trauma is amenable to radiological control, as long as blood loss is greater than 0.5 mL/min. For the safe management of the patient in an isolated environment, the patient must be relatively stable; the ideal 'El Dorado' is a set-up in radiology which is the same as in a theatre or ICU.
Professor Monty Mythen spoke on the 'state of the art' in fluid resuscitation in trauma. Early restoration of heart-lung circulation is essential for short-term survival; restoration of the complete circulation essential for long-term survival. Available evidence points to the importance of hypotensive resuscitation until haemorrhage is controlled. The end point for a fluid bolus is a palpable pulse; the best fluid to achieve this is debatable. Available evidence would suggest that isotonic crystalloid is the best fluid, and that albumin should be avoided.
The final talk in this session was about the use of hypothermia in traumatic head injury. Dr Kees Polderman' s message was that all processes in secondary brain injury are temperature dependent. In traumatic brain injury, which itself causes brain temperature to rise, potential damage is worsened. There is increasing evidence in perinatal asphyxia and post adult cardiac arrest that hypothermia is beneficial in brain injury. He identified some fundamental flaws in the design of previous studies refuting the importance of hypothermia in brain injury, including long mean times to temperature control and large numbers of hypotensive episodes. If data is analysed by numbers of patients enrolled and only large centres included, there is a positive effect of hypothermia in this context.
The next session dealt with weaning from mechanical ventilation. Dr Wes Ely from Nashville enlivened the audience with a dynamic talk on weaning protocols and the 'ABC' study. He started from the premise that the best evidence at present shows that sedation 'holidays' are beneficial, and that weaning protocols shorten time on a ventilator. However previous trials have not examined both together; the ABC trial set out to do so. If these two interventions are combined then there may be a benefit, with an increase in ventilator-free days and a reduction both in time to ICU discharge and hospital length-of-stay.
Dr Michael Polkey had advice on strategies for the 'problem' weaning patient. He has the unenviable task of accepting referrals of patients who are difficult to wean from ventilatory support. He stressed that trials of spontaneous breathing for as little as 20 minutes can be helpful in improving respiratory muscle function. He also highlighted the importance of optimising physiological and psychological function. The patient' s family have an important role to play. Rather than a specific weaning protocol, the most important feature is to have a protocol and to use it.
Further advice on separating patients from their ventilators came from Professor Laurent Brochard in a presentation on 'automated weaning.' He described a ventilator that relies on proportional servo valves and works on a knowledge-based system which allows automated weaning of patients. One trial shows this to be comparable to clinical decision-making and to lead to a shorter duration of ventilation and ICU length-of-stay.
On the subject of spinal injuries and weaning, Dr Fox was tempted to give a very short talk that encapsulated weaning after spinal cord injuries -"take them off the ventilator, put them back on, take them off…." Happily he decided to elaborate. There are 800-1,000 new spinal injuries a year in the UK, of which 50% are cervical. The natural history of cervical cord injuries is that vital capacity gets worse before it gets better. C5-8 lesions should be weanable in 14 days and C4 and above in about 60 days. Improvements in respiratory function can be achieved by the use of bronchodilators to pharmacologically replace the lost sympathetic input. There is also counterintuitive evidence that patients receiving tidal volumes of >20 mL/kg were weaned in half the time of patients receiving conventional tidal volumes. Due to the high mortality in patients who remain hospitalised at one year, it is important to refer difficult patients early.
After lunch, Dr Jerry Nolan presented new concepts in resuscitation. These include: increased integration of technology to improve team performance, with automated verbal feedback; mechanical compression devices; improved software to allow filtering of compression artefact leading to a cleaner ECG signal. The major change is the emphasis on the minimisation of the pre-shock pause to increase the chances of successful defibrillation. Indeed, some cardiac physiologists are measuring leakage currents whilst chest compressions are continued, although with a pair of latex gloves to protect them! He ended with a view of the future -regional centres for
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post-cardiac arrest care and implementation of standardised care. In a logical progression, Dr Kees Polderman continued with 'Hypothermia: outcomes in practice,' in which he discussed the significance of the time to cooling after cardiac arrest as a therapeutic window which should be targeted to improve outcome. The length of time to maintain hypothermia is unclear but the current evidence is that the NNT for cooling benefit is six. To complete the session, Dr David Harrison led us through what we can learn about cardiac arrest from the ICNARC database. Currently 5.8% of all ICU admissions follow cardiac arrest. Age is increasing, as is unit-and hospitallength-of-stay which may correlate with an increased comorbidity in in-hospital arrests. There is a small increase in the trend for treatment withdrawal, but the time to treatment withdrawal has remained the same at approximately four days. There is wide variation between units in the incidence of admission of patients post cardiac arrest, which needs further study.
The Industry Symposium, sponsored by Eli Lilly, was about genomics and proteomics of activated protein C (Xygris). The state of research relating to protein C and the therapeutic benefits of recombinant human activated protein C (rhAPC) were reviewed, and Dr Anthony Gordon described the improved benefit-to-risk ratio of treatment with rhAPC for certain genotypes, and its use in predicting the population of patients that will respond to rhAPC. Dr Jonathan James reviewed data from the PROWESS and ENHANCE studies, and described how these had been used to design the RESPOND trial. This is a phase II study that will attempt to answer the questions of who to treat, how much to give and how long to treat. Dr Andrew Rhodes described the protocol for the PROWESS shock study. The study is being conducted in a transparent manner, with publication of the protocol in advance of the study.
At the same time, Dr Kevin Gunning chaired a session on analgesia-led sedation and the ULTISAFE study. Professor Jan Bakker presented the results of the study that showed patients on a remifentanil-based analgesia and sedation regimen are almost twice as likely to be extubated and discharged from ICU within the first three days compared to a conventional regimen, and that the regimen is cost-effective.
In the plenary session, Dr Wes Ely gave an impassioned talk on delirium and the long term cognitive impairment in ICU patients. This important organ dysfunction has been shown to be an independent predictor of hospital length of stay and death, and is particularly likely in an ageing ICU population who have decreased neuro-plasticity. However, there is no standardised monitoring of delirium on the ICU and he encouraged clinicians to monitor state of arousal with a sedation score and to add a delirium score. He gave a brief description of the latest published studies and ended by pointing out the importance of sleep and how slow-wave sleep is abolished by drugs commonly used for sedation.
The Gillian Hanson lecture was 'PEEP in ARDS: a long story' by Professor Laurent Brochard. This was a fascinating discourse on the introduction of PEEP to clinical practice to the use of PEEP in current practice.
Tuesday started with double espressos from the trade stands and reports of new clinical trials. Dr Mark Bonten discussed the results of the effects of Selective Decontamination of the Digestive (SDD) tract and Selective Oropharyngeal Decontamination (SOD) on patient survival in Dutch ICUs. Dr Bloos then presented the results of the Volume resuscitation and Insulin therapy in Sepsis (VISEP) trial, the conclusion of which was that 10% HES solutions should not be used in patients with severe sepsis because of consequent renal dysfunction, and that intensive insulin therapy is not safe in this group of patients because of hypoglycaemia. Dr Wes Ely closed the session with a summary of the MENDS trial, which demonstrated a benefit in the use of α 2 -receptor agonists instead of more conventional GABA receptor agonists in the length of time of delirium. His request to be roasted at the end of his presentation was responded to with some challenging questions. The next session, 'Critical care into the next decade', provided a somewhat frightening vision of the future of intensive care. This started with Professor Kathy Rowan predicting the future demands for ICU extrapolating from the ICNARC database. When modelled for population predictions and modified for age, sex, increasing ICU admissions and changes in disease prevalence this suggests that a massive increase in bed numbers from 2,000 to 6,000 is required by 2031. Dr Jim Wardrobe continued to raise anxiety levels with a review of the main points from the Academy of Medical Colleges' Report on Acute Health Care Services which identified that decisions on services need to be based at a local level, but acknowledged that some specialist services need to be centralised.
The flames were fanned by a presentation on regionalisation of critical care by Dr Andrew Webb, when he suggested that larger tertiary ICUs may be more efficient because of their greater degree of flexibility to match demand fluctuations and their ability to provide better training. He did acknowledge that, for this to be a reality, there would need to be a vast increase in the ability of these ICUs to retrieve patients. To ensure that the delegates remained unsettled, Dr John Coakley spoke on 'Changing the role of critical care'. He described a system where there is a much greater integration between the specialties involved in emergency work, with the development of an Acute Care Team who are freed from elective duties and are able to dedicate their time to care of acutely ill patients.
Dr Andrew Cadamy had a panoply of professors to manage in his session about 'How to manage…'. Professor Marc Bolan gave a discourse on how he diagnoses ventilator-associated pneumonia, Professor Daniel Kett on how he diagnoses and manages heparin-induced thrombocytopaenia in critically ill patients and Professor Mervyn Singer on how he treats cardiogenic shock.
The Industry symposium 'Guidelines on intravenous fluid therapy for surgical patients: towards a national consensus' was sponsored by B Braun Medical and chaired by Professor Monty Mythen, who described the consensus process and summary of the guidelines on intravenous fluid therapy for surgical patients. Mr Dileep Lobo provided a surgical view of 'abnormal' saline which was followed by Dr Rupert Pearse with the intensivist' s view; both agreed that prescribing fluid can be Reports difficult and further education is necessary.
The 'Thrombosis and thromboprophylaxis' session opened with an update on the best management of acute coronary syndrome by Dr Howard Swanton. This was followed by Dr Peter Sandercock on recommendations for thrombolysis in acute ischaemic stroke, suggesting three hour thrombolysis cut-off with NNT=6. Dr Beverley Hunt spoke about the high incidence of DVT in critically ill patients and highlighted the importance of VTE prophylaxis. The final presentation of the session was from Professor Tim Walsh who presented data from the IsoC study group on coagulopathies in ICU. This provided evidence that FFP is used on ICUs at a dose that is likely to be sub-therapeutic in patients with active haemorrhage and abnormal clotting. Of greater interest is the widespread use of FFP for patients who are not bleeding and in some cases had normal coagulation.
The final session was 'Lessons from studies of physiology under extreme conditions.' Mike Grocott gave an insight into the Caudwell Extreme Everest Expedition and tantalised us with some of the early data from the largest high-altitude physiology study and how it may help the understanding of hypoxia in critically ill patients. Professor Iain Mackenzie concluded the conference with an account of the difficulties of escorting a quadriplegic patient for a zero-gravity training flight.
Reports
Matt Hill Specialist Registrar, Plymouth mattrhill@yahoo.co.uk M any members of the Intensive Care Society who have attended our meetings over the last two decades will have strong recollections of Tony Whitaker from Mansfield, who was renowned for his legendary, and often quite unpredictable, questions or feedback comments. For speakers these were frequently quite challenging, but many also valued the resulting discussion points which often created greater insight and interest in their chosen topics, and we will all greatly miss Tony' s participation as a consequence of his early death from pancreatic cancer last year.
It was an unanticipated but welcome surprise when we learned that Tony had made a donation to the Society in his will, and discussions have taken place about how this should be used. A suggestion, which is supported by Council, and for which we hope there will be similar support amongst the membership, is the creation of the Whitaker Award. After nomination by members, this award will be allocated by Council to an individual or individuals who have made unusual or exceptional contributions to the specialty of intensive care medicine.
These contributions may not necessarily be clinical-or research-based, but also in the wider framework of our specialty: contributions benefitting patient safety, training, public understanding, staff morale, etc. Although the preference is that the award is made annually, it has also been agreed that it will not be awarded if a relevant nomination has not been received. The details of the award symbol have yet to be determined, but it should be clarified that this will be a symbol of achievement and will not be associated with any additional financial reward! Unless there are any objections to this proposal it is anticipated that the first Whitaker Award will be made at the State of the Art Meeting in December 2008. If any of Tony Whitaker' s colleagues have any thoughts on what might have been his preference for an icon to represent the award, please don't hesitate to contact me.
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